Franck Bonnetain

TL;DR: Preoperative chemoradiotherapy despite a moderate increase in acute toxicity and no impact on overall survival significantly improves local control and is recommended for T3-4, N0-2, M0 adenocarcinoma of the middle and distal rectum.

TL;DR: It is suggested that, in patients with locally advanced thoracic esophageal cancers, especially epidermoid, who respond to chemoradiation, there is no benefit for the addition of surgery after cheMoradiation compared with the continuation of additional chemorADiation.

TL;DR: In this open-label, randomized trial involving patients with locally advanced pancreatic cancer with disease controlled after 4 months of induction chemotherapy, there was no significant difference in overall survival with chemoradiotherapy compared with chemotherapy alone and there wasno significant difference with gem citabine compared with gemcitabine plus erlotinib used as maintenance therapy.

TL;DR: This intensive induction schedule of CHRT was more toxic and less effective than gemcitabine alone and was confirmed in a per-protocol analysis for patients who received 75% or more of the planned dose of radiotherapy.

TL;DR: An in vivo role for immune (particularly NK cell) responses in the mechanism of trastuzumab action in breast cancer is supported, which may partially account for the synergistic activity of trastsizumab and docetaxel in Breast cancer.